Cardiovascular risk stratification, arrhythmias, coronary artery disease, and hemodynamics.
Calculates reference values for walk distance as a measure of functional status in cardiopulmonary diseases
Describes heart failure stages and provides stage-specific therapy recommendations, based on ACC/AHA/HFSA guidelines
Predicts 30-day mortality after elective or emergency cardiac surgery, incorporating age, creatinine, ejection fraction, emergency status, and pre-operative anemia.
Predicts risk of NSTEMI complications requiring ICU care. This is a prognostic tool for emergency patients with non-ST elevation myocardial infarction (NSTEMI) to assess their risk of developing complications that would require intensive care unit (ICU) management.
Predicts in-hospital mortality in patients hospitalized with acute decompensated heart failure (ADHF). This is a simple decision tree algorithm that uses three readily available clinical parameters to risk-stratify heart failure patients.
ACC/AHA 2017 blood pressure categories for adults.
Screens for peripheral artery disease by comparing ankle and brachial systolic pressures. Computed per leg; repeat for the contralateral leg.
Rules out aortic dissection based on clinical risk factors. A guideline-based tool for identification of acute aortic dissection at initial presentation developed from the International Registry of Acute Aortic Dissection (IRAD).
Grades aortic stenosis severity (mild / moderate / severe) from echocardiographic peak velocity, mean gradient, and aortic valve area per ACC/AHA criteria. Flags discordant grading instead of silently averaging.
CaO2: total arterial oxygen content.
Estimates the 10-year risk of atherosclerotic cardiovascular disease (heart attack, stroke, or death due to coronary heart disease or stroke) using the Pooled Cohort Equations. For patients 40-79 years old with no history of ASCVD.
Determines bleeding risk for patients on warfarin therapy for atrial fibrillation. The score was developed and validated in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort and helps stratify patients into low, intermediate, and high risk categories for major hemorrhage.
Determines stroke risk in patients with atrial fibrillation. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) stroke risk score predicts ischemic stroke and other thromboembolism in patients with atrial fibrillation, helping guide anticoagulation decisions.
Stratifies cardiovascular risk of patients undergoing noncardiac surgery using 6 easily obtainable clinical variables with superior discriminatory power compared to other risk indices.
Distinguishes ventricular tachycardia from supraventricular tachycardia with aberrancy using ECG morphology criteria
Brugada 4-step algorithm to distinguish VT from SVT with aberrancy.
Body surface area by the DuBois & DuBois formula (hemodynamic calculations).
Predicts poor prognosis after out-of-hospital cardiac arrest and guides utility of cardiac catheterization
Calculates cardiac output, cardiac index, and stroke volume using Fick's principle. The gold standard method for measuring cardiac output based on oxygen consumption and arteriovenous oxygen difference.
Calculates cardiac power output, the rate of energy output of the heart. Integrates both pressure and flow components of cardiac work. Strong hemodynamic predictor of mortality in cardiogenic shock.
The CARE Score predicts mortality and morbidity after cardiac surgery. It is a simple risk classification based on clinical judgment and three clinical variables: comorbid conditions (controlled vs uncontrolled), surgical complexity, and urgency of the procedure.
The Canadian Cardiovascular Society (CCS) Angina Grade classifies the severity of exertional angina based on the degree of effort necessary to induce angina symptoms. This standardized grading system helps clinicians communicate about functional limitations and symptom severity in patients with coronary artery disease.
Calculates stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex. Simplified version recommended in 2024 ESC guidelines to remove complexity of gender-based scoring.
Calculates the risk of stroke in patients with non-valvular atrial fibrillation, aiding in the decision regarding oral anticoagulation
Clinical prediction tool that estimates annual stroke risk in patients with atrial fibrillation. Helps determine whether anticoagulation therapy is warranted based on patient's risk profile for thromboembolic events. Developed from the National Registry of Atrial Fibrillation and validated in multiple populations.
Clinical decision algorithm developed by the Canadian Cardiovascular Society to guide antithrombotic therapy for patients with nonvalvular atrial fibrillation or atrial flutter. Uses age-based approach to determine whether patients should receive oral anticoagulation, antiplatelet therapy, or no antithrombotic therapy for stroke prevention.
Corrects QT interval for heart rate extremes using multiple validated formulas (Bazett, Fridericia, Framingham, Hodges, or Rautaharju)
Risk stratifies patients with NSTEMI undergoing anticoagulation to determine their risk of major bleeding during hospitalization
Predicts which patients will benefit from prolonged DAPT after coronary stent placement. Developed from the DAPT Study randomized trial to predict combined ischemic and bleeding risk for patients being considered for continued thienopyridine therapy beyond 1 year.
Predicts bleeding risk in patients with atrial fibrillation on direct-acting oral anticoagulants
Estimates functional capacity of patients through self-reported activities. A 12-item questionnaire that assesses daily activities with respective metabolic costs to predict maximal oxygen consumption (VO2 max) and maximum metabolic equivalent of tasks (METs).
Diagnoses and prognoses suspected coronary artery disease (CAD) based on treadmill exercise test. Uses exercise time, ST deviation, and angina to predict prognosis and guide further treatment decisions.
Predicts likelihood that syncope is of cardiac cause to help emergency clinicians with screening and risk stratification in patients presenting with syncope.
EHRA symptom classification for atrial fibrillation.
Pulmonary arterial hypertension 4-strata risk (ESC/ERS 2022).
Determines risk of right ventricular heart failure in patients after left ventricular assist device (LVAD) implantation.
Predicts risk of in-hospital mortality after major cardiac surgery using logistic regression model with 18 validated variables.
Diagnoses heart failure based on major and minor criteria. Requires at least 2 major criteria or 1 major criterion plus 2 minor criteria.
Estimates 10-year risk of myocardial infarction in patients aged 30-79 with no history of coronary heart disease or diabetes
LDL = TC - HDL - TG/5 (mg/dL).
The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.
Staging system for transthyretin amyloid cardiomyopathy using NT-proBNP and estimated glomerular filtration rate (eGFR) to stratify patients into prognostic categories for both wild-type and variant ATTR-CM
Estimates admission to 6-month mortality risk for patients with acute coronary syndrome. Uses 8 clinical variables to provide risk stratification and guide treatment decisions in both ST-elevation and non-ST-elevation ACS.
Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T
Predicts all-cause in-hospital mortality in admitted patients with heart failure using validated AHA Get With The Guidelines data
Estimates probability of heart failure with preserved ejection fraction (HFpEF) in euvolemic patients with unexplained exertional dyspnea who have had an echocardiogram. Uses clinical characteristics and echocardiographic parameters to distinguish HFpEF from noncardiac causes of dyspnea.
Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.
Identifies emergency department patients with acute chest pain for early discharge. Combines HEART score with serial troponin measurements to risk-stratify patients.
Identifies emergency department chest pain patients suitable for early discharge: HEART score <=3 with negative serial troponins.
Predicts 6-week risk of major adverse cardiac events in patients presenting with chest pain in the emergency department.
Heart Failure Association PEFF score for diagnosing heart failure with preserved ejection fraction from functional, morphological and biomarker domains.
Predicts 6-month mortality in patients with infective endocarditis using validated clinical parameters. This risk stratification tool was developed from the International Collaboration on Endocarditis (ICE) Prospective Cohort Study and helps clinicians assess prognosis and guide treatment decisions in patients with definite infective endocarditis. The score incorporates host factors, IE characteristics, and complications to provide mortality risk prediction.
Rules out coronary artery disease (CAD) in primary care patients 30 years and older presenting with chest pain. This clinical prediction rule is designed to identify patients with very low likelihood of chest pain due to unstable CAD, allowing for safe discharge without further urgent evaluation. The rule uses 6 clinical variables with scores ranging from -1 to +5. Scores ≤1 indicate low CAD risk (2.1% probability) with 98% negative predictive value, while scores ≥2 indicate higher risk (43% probability) requiring further evaluation. This tool is specifically for primary care settings and should not be used for positive diagnosis of CAD or in emergency settings.
Diagnoses acute rheumatic fever based on major and minor criteria with evidence of antecedent group A streptococcal infection. The revised 2015 criteria require evidence of streptococcal infection plus either 2 major criteria OR 1 major and 2 minor criteria.
Bedside classification of heart failure severity in acute myocardial infarction; predicts mortality.
Quantifies heart failure severity in acute coronary syndrome (STEMI or NSTEMI) and predicts 30-day mortality. Based on physical examination findings to stratify risk in myocardial infarction patients.
Calculates LDL cholesterol using the Friedewald formula based on total cholesterol, HDL cholesterol, and triglycerides. Used for cardiovascular risk assessment and lipid management when direct LDL measurement is not available
Calculates LVEF from end-diastolic and end-systolic volumes.
Estimates 1- and 3-year mortality in heart failure patients
Rules out coronary artery disease in primary care patients aged 35 years and older presenting with chest pain. Uses five equally weighted clinical criteria to stratify patients into low-risk (score 0-2) or higher-risk (score ≥3) categories for CAD assessment. Designed specifically for primary care settings to guide appropriate referral decisions.
Estimates maximum heart rate (220 - age) and 5 training zones.
Calculates the average arterial pressure during one cardiac cycle using systolic and diastolic blood pressure. MAP is a better indicator of tissue perfusion than systolic blood pressure alone.
Predicts risk of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI). The score uses 8 clinical variables to stratify patients into risk categories and guide preventive strategies.
Mitral regurgitation severity grading per ASE 2017: vena contracta width, effective regurgitant orifice area (EROA), regurgitant volume (RVol), and regurgitant fraction (RF). Overall grade = worst parameter (fail-safe direction).
Diagnoses acute myocardial infarction in patients with prior left bundle branch block using ECG criteria with improved sensitivity over the original Sgarbossa criteria.
Stratifies severity of heart failure by symptoms. Provides a simple way of classifying the extent of heart failure based on physical activity limitations and symptoms.
ORBIT bleeding risk score for atrial fibrillation (O'Brien 2015): Older age ≥75 (1), Reduced hemoglobin/anemia (2), Bleeding history (2), Insufficient kidney function eGFR <60 (1), Treatment with antiplatelet (1); total 0-7. 0-2 low, 3 medium, ≥4 high bleeding risk.
Revised Cardiac Risk Index (Lee 1999) for perioperative cardiac risk: 6 factors × 1 point — high-risk surgery, ischemic heart disease, CHF, cerebrovascular disease, diabetes on insulin, creatinine >2.0 mg/dL. 0: 0.4%, 1: 0.9%, 2: 6.6%, ≥3: 11% major cardiac event risk.
ECG point system for left ventricular hypertrophy: >= 5 points LVH, 4 probable.
Grades peripheral artery disease severity: categories 0-6.
Predicts poor anticoagulation control on warfarin: 0-2 adequate TTR likely, >2 poor.
Predicts 10-year risk of cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) in patients aged 40-69 without prior cardiovascular disease or diabetes.
Predicts 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease.
Predicts 5-year and 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in individuals aged 70 years and older without prior cardiovascular disease, accounting for competing risks.
Calculates stroke volume (SV): the volume of blood ejected by a ventricle per beat, as end-diastolic volume minus end-systolic volume. Normal resting SV is approximately 50-100 mL/beat; interpretation depends on body size and clinical context.
Differentiates normal variant ST elevation (benign early repolarization) from anterior STEMI in patients with chest pain and non-diagnostic ECG changes. This sensitive tool helps identify patients with subtle anterior wall MI who may benefit from urgent percutaneous coronary intervention.
Predicts risk of acute kidney injury (AKI) requiring dialysis after cardiac surgery. The score was developed and validated in over 33,000 patients at the Cleveland Clinic Foundation.
Estimates 30-day mortality in ST-elevation MI using 8 clinical variables (0-14 points). Derived from the InTIME II trial; helps risk-stratify STEMI patients at presentation.
Estimates 30-day risk of death, myocardial infarction, or urgent revascularization in patients with unstable angina or non-ST-elevation MI. Helps triage to early invasive vs. conservative strategy.
Rules out acute coronary syndrome using high-sensitivity cardiac troponin T and clinical factors. Provides risk stratification for patients presenting with chest pain to the emergency department.
Diagnoses familial hypercholesterolemia using age-specific total cholesterol cutoff values that vary based on family history of FH. The US MEDPED (Make Early Diagnosis to Prevent Early Death) criteria provide a simplified approach to FH diagnosis using only total cholesterol levels and family history.
Venous oxygen content (CvO2): oxygen carried in venous blood = hemoglobin-bound (1.34 × Hb × SvO2) plus dissolved (0.003 × PvO2). Used with arterial content for arteriovenous O2 difference and Fick cardiac output.
Vereckei lead-aVR algorithm (2008) for the differential diagnosis of wide-QRS tachycardia (VT vs SVT with aberrancy). Four sequential criteria; the first positive criterion diagnoses VT: (1) AV dissociation, (2) initial R wave in aVR, (3) QRS morphology not typical of bundle branch block, (4) Vi/Vt ≤1. If all negative → SVT with aberrancy.
The VIRSTA Score is a clinical decision tool used to risk-stratify suspected infective endocarditis cases before obtaining echocardiography. This score helps identify patients at very low risk for infective endocarditis who may not require immediate echocardiographic evaluation, thereby reducing unnecessary testing and healthcare costs while maintaining diagnostic safety.
Estimates VLDL cholesterol via the Friedewald equation (VLDL = triglycerides / 5, in mg/dL). Valid only when triglycerides are <400 mg/dL and the sample is fasting; inaccurate in hypertriglyceridemia and type III hyperlipoproteinemia.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.